Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer

AI Briefing

• – Crossbow raises $77M in Series B financing to advance TCR-mimetic antibody therapies for cancer treatment.
• – The funding will support the development of new cancer therapies.
• – The company will use the funds to accelerate the advancement of its pipeline of TCR-mimetic antibody therapies.